Download Free Medical CHOLINERGIC DRUGS PowerPoint Presentation

CHOLINERGIC DRUGS PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Pharmacology, which is titled "Cholinergic Drugs", to know about cholinergic drugs.

Tags : Pharmacology, Cholinergic Drugs

Published on : Jul 18, 2021 | Views : 3400 | Downloads : 27

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

CHOLINERGIC DRUGS (Parasympathomimetics, Cholinomimetics) Assoc. Prof. I. Lambev E-mail: itlambev@mail.bg
Slide 2-

The motor (efferent) portion of the nervous system can be divided into two major subdivisions: autonomic and somatic. The autonomic nervous system (ANS) is largely independent in that its activities are not under direct conscious control. It is concerned primarily with visceral functions such as cardiac output, blood flow to various organs, and digestion, which are necessary for life. The somatic division is largely concerned with consciously controlled functions such as movement, respiration, and posture. Nerve impulses elicit responses in smooth, cardiac, and skeletal muscles, exocrine glands, and postsynaptic neurons by liberating specific chemical neurotransmitters.
Slide 3-

By using drugs that mimic or block the actions of chemical transmitters, we can selectively modify many autonomic functions. These functions involve a variety of effector tissues, including cardiac muscle, smooth muscle, vascular endothelium, exocrine glands, and presynaptic nerve terminals. Autonomic drugs are useful in many clinical conditions.
Slide 4-

The ANS has two major portions: the sympathetic (thoracolumbar) division and the parasympathetic (craniosacral) division. Both divisions originate in nuclei within the CNS and give rise to preganglionic efferent fibers that exit from the brain stem or spinal cord and terminate in motor ganglia. The sympathetic preganglionic fibers leave the CNS through the thoracic and lumbar spinal nerves. The parasympathetic preganglionic fibers leave the CNS through the cranial nerves (especially the third, seventh, ninth, and tenth) and the third and fourth sacral spinal roots.
Slide 5-

ppt slide no 5 content not found
Slide 6-

Parasympathetic nerves regulate processes connected with energy assimilation (food intake, digestion, absorption) and storage. These processes operate when the body is at rest, allowing increased bronchomotor tone and decreased cardiac activity. Secretion of saliva and intestinal fluids promotes the digestion of foodstuffs; transport of intestinal contents is speeded up because of enhanced peristaltic activity and lowered tone of sphincter muscles. To empty the urinary bladder (micturition), wall tension is increased by detrusor activation with a concurrent relaxation of sphincter tonus.
Slide 7-

Activation of ocular parasympathetic fibers results in nar- rowing of the pupil and increased curva- ture of the lens, enabling near objects to be brought into focus (accommodation).
Slide 8-

ACh serves as mediator at terminals of all postganglionic parasympathetic fibers, in addition to fulfilling its trans- mitter role at ganglionic synapses with- in both the sympathetic and parasym- pathetic divisions and the motor end- plates on striated muscle. However, dif- ferent types of receptors are present at these synaptic junctions.
Slide 9-

CHOLINERGIC NERVES
Slide 10-

ACh is highly concentrated in synaptic storage vesicles present in the axoplasm of the terminal. ACh is formed from choline and activated acetate acetylcoenzyme A, a reaction catalyzed by the enzyme choline acetyltransferase. The highly polar choline is actively transported into the axoplasm. The specific choline transporter is localized exclusively to membranes of cholinergic axons and terminals.
Slide 11-

ppt slide no 11 content not found
Slide 12-

During activation of the nerve membrane, Ca2+ enters into the axoplasm through voltage-gated channels to activate protein kinases. As a result, vesicles close to the presynaptic membrane and fuse with this membrane. During fusion, vesicles discharge their contents into the synaptic gap. ACh quickly diffuses through the synaptic gap. The molecule of ACh is a little longer than 0.5 nm. The synaptic gap is as narrow as 30–40 nm.
Slide 13-

At the postsynaptic effector cell membrane, ACh reacts with its receptors. Because these receptors can also be activated by the alkaloid muscarine, they are referred to as muscarinic (M-) cholinoceptors. In contrast, at ganglionic and motor endplate cholinoceptors, the action of ACh is mimicked by nicotine and they are, therefore, said to be nicotinic (N-) cholinoceptors. Released ACh is rapidly hydrolyzed and inactivated by a specific acetylcholine esterase, present on pre- and postjunctional membranes, or by a less specific serum choline esterase (butyryl choline esterase), a soluble enzyme present in serum and interstitial fluid.
Slide 14-

ppt slide no 14 content not found
Slide 15-

M-cholinoceptors can be classified into subtypes according to their molec- ular structure, signal transduction, and ligand affinity in the M1, M2, M3 subtypes, etc. M1-receptors are present on nerve cells, e.g., in ganglia, where they mediate a facilitation of impulse transmission from preganglionic axon terminals to ganglion cells. M2-receptors mediate acetylcholine effects on the heart. Opening of K+ channels leads to slowing of diastolic depolarization in sinoatrial pacemaker cells and a decrease in heart rate.
Slide 16-

M3-receptors are found in the glandular epithelia (which respond with activation of phospholipase C and increases secretory activity) and in smooth muscle. In smooth vessels, the relaxant action of ACh on muscle tone is indirect, because it involves stimulation of M3-cholinoceptors on endothelial cells that respond by liberating NO. In the CNS, where all subtypes are present, cholinoceptors serve diverse functions, including regulation of cortical excitability, memory, learning, pain processing, and brain stem motor control.
Slide 17-

Muscarinic receptor (G protein-linked: 7 subunits)
Slide 18-

Presynaptic regulation of transmitter release from noradrenergic and cholinergic nerve terminal
Slide 19-

Characteristic of Nicotinic receptors NM-cholinoceptors Location: neuromuscular junction Function: depolarization of muscle end plate and contraction of skeletal muscle NN-cholinoceptors Location: autonomic ganglia Function: depolarization postganglonic membrane (in adrenal medula – catecholamine release)
Slide 20-

The NM-receptor is a macroprotein with 5 subunits, which are arranged like a rosette surrounding the Na+ channel. The two alpha subunits carry two ACh binding sites with nega- tively charged groups which combine with the cationic group of ACh and open Na+ channel.
Slide 21-

N-receptor: 5 subunits
Slide 22-

Acetylcholine receptor stimulants and cholinesterase inhibitors together comprise a large group of drugs that mimic ACh (cholinomimetic agents) Cholinoceptor stimulants are classified by their spectrum of action depending on the type of receptor – muscarinic or nicotinic, that is activated. They are also classified by their mechanism of action because some cholinomimetic drugs bind directly to (and activate) cholinoceptors, while others act indirectly by inhibiting the hydrolysis of endogenous ACh.
Slide 23-

I. DIRECT-ACTING CHOLINERGIC DRUGS (1) Choline ester (stimulants of M- and N-receptors): Acetylcholine, Carbachol, etc. (2) Alkaloids a) stimulants of M-receptors: Pilocarpine, Cevimeline (dry mouth), Bethanechole, Musacarine, Phalloidin b) stimulants of N-receptors: Nicotine, Cytisine (Tabex®), Lobeline
Slide 24-

N4+ Ionization!!! BBB
Slide 25-

50 100 150 200 A B C D 1 min M- и N-effects of ACh Blood pressure [mm Hg] ACh 2 mcg i.v. ACh 50 mcg ACh 50 mcg ACh 5 mg M- effect M- effect N- effect Atropine 2 mg i.v.
Slide 26-

ppt slide no 26 content not found
Slide 27-

Pilocarpus jaborandi Pilocarpine - in glaucoma
Slide 28-

Pilocarpine Hydrochloride eye drops (Pilocar®) - sol. 1%, 2%, 4% - in open angle glаucoma Applied to the eye, it penetrates cornea and promptly causes miosis, ciliary muscle contra- ction, and fall in intraoccular tension (< 22 mm) lasting 4-8 h. Side effect: painful spasm of accommodation for near vision. Systemic effects: sweating, salivation Cardiovascular effects: in small doses – fall in BP, but in high doses elicits rise in BP and tachycardia, probably due to ganglionic stimulation (through muscarinic receptors)
Slide 29-

Development of angle closure glaucoma and its reversal by miotics A. Mydriasis occurs in an eye with narrow iridocorneal angle and the iris makes contact with the lens blocking passage of theaqueous from the posterior to the anterior chamber. B. Possibly builds up behind the iris which bulges forward and closes the iridocorneal angle thus blocking aqueous outflow. C. Miotic makes the iris thin and pushes it away from the lens removing the pupillary block and restoring aqueous drainage.
Slide 30-

Autonomic control of pupil (A) and site of action of mydriatics (B) and miotics (C)
Slide 31-

Amanita muscaria: muscarine Amanita phalloides: phalloidine
Slide 32-

Cytisus laburnum L. Cytisine Nicotiana tabacum L. Nicotine
Slide 33-

Cytisine (Tabex® p.o.) Nicorette (chewing gum) Nicotinell® TTS
Slide 34-

ppt slide no 34 content not found
Slide 35-

II. INDIRECT-ACTING CHOLINERGIC DRUGS (anticholinesterase drugs: antiChEs) (1) Reversible drugs (most are carbamates) a) With N3+ (cross BBB) Alkaloids: Galantamine, Physostigmine Synthetic drugs: Donepezil, Rivastigmine, Tacrine b) With N4+ (do not cross BBB) Demecarium, Edrophonium (Tensilon®) Neostigmine, Pyridostigmine
Slide 36-

(2) Irreversible anticholinesterase agents (most of them are organophosphates) a) Thiophosphate insecticides Parathion Malathion (Pedilin® – used in pediculosis) b) Nerve paralytic gases for chemical warfare: Tabun Sarin Soman cockroach
Slide 37-

Representative "reversible" anticholinesterase agents employed clinically
Slide 38-

ppt slide no 38 content not found
Slide 39-

AntiChEs inhibit ChE and protect ACh from hydrolysis. They produce cholinergic effects and potentiates ACh both in vivo and in vitro. Lipid soluble agents (physostigmine and organophosphates) have more marked muscarinic and CNS effects, stimulates ganglia but action on skeletal muscles is less prominent (NB: the action of Galantamine on skeletal muscles is much stronger in comparison with neostigmine).
Slide 40-

Lipid insoluble antiChEs (neostigmine and other quaternary ammonium compounds) produce more marked effect on the skeletal muscles (direct action on muscle end-plate NN-cholinoceptors as well). Stimulate ganglia but muscarinic effects are less prominent. They do not penetrate in CNS and have no central effects.
Slide 41-

Prof. D. Paskov (1914–1986) Galantamine (Nivalin®) Galantamine is antiChEs with direct N-action used in: Myastenia gravis Alzheimer’s disease Poliomyelitis Postoperative paresis of GIT and bladder As antagonist of competitive myorelaxants with less side effects than neostigmine
Slide 42-

Myasthenia gravis (MG) is a disease affecting skeletal muscle neuromuscular junctions. An autoimmune process causes production of antibodies that bind to the a subunits of the nicotinic receptor. This effect causes accelerated degradation of the receptor and blockade of ACh binding to receptors on muscle end plates. Frequent findings are ptosis, diplopia, difficulty in speaking and swallowing, and extremity weakness. Severe disease may affect all the muscles, including those necessary for respiration. The disease resembles the neuromuscular paralysis produced by tubocurarine and similar nondepolarizing neuromuscular blocking drugs. Patients with myasthenia are sensitive to the action of curariform drugs and other drugs that interfere with neuromuscular transmission e.g., aminoglycoside antibiotics. Anti-ChEs are extremely valuable as therapy for myasthenia. Almost all patients are also treated with immunosuppressant drugs and some with thymectomy. Edrophonium is used as a diagnostic test in myasthenia gravis.
Slide 43-

Diagrams of (A) normal and (B) myasthenic neuromuscular junctions. The MG junction has a normal nerve terminal; a reduced number of AChRs and a widened synaptic space.
Slide 44-

In the Alzheimer’s disease in the brain tissue there are amyloid plaques and neurofibrillarly tangles, as well as loss of cholinergic neurons. Cholinacetyl trasferase activity in the cortex and hippocampus is reduced from 30% to 70%. Loss of cholinergic neurons contributes for to much of the learning and memory deficit. The number of M-cholinoceptors is not affected, but the number of N-receptors is reduced.
Slide 45-

Enlargement ventricles Diminished hypothalamus Thin brain cortex Alzheimer's disease
Slide 46-

Reversible anti-AChEs used in: Glaucoma: pilocarpine, demecarium Myasthenia gravis: edrophonium, galantamine, neostigmine, physostigmine, pyridostigmine Alzheimer’ disease: donepezil, galantamine, aminopyridine (Pymadine®), rivastigmine, tacrine Postoperative paralytic ileus or/and urinary retention: galantamine, neostigmine Postoperative decurarization: galantamine, neostigmine, pymadine (it releases ACh!) Belladonna poisoning: physostigmine, neostigmine, galantamine Cobra bite (cobra venom has a curare-like neurotoxin): galantamine, neostigmine
Slide 47-

Reactivators of ChE used for the treatment of intoxication with organophosphates